CN1162404C - Process for the synthesis of intermediates useful in the preparation of tricyclic compounds - Google Patents
Process for the synthesis of intermediates useful in the preparation of tricyclic compounds Download PDFInfo
- Publication number
- CN1162404C CN1162404C CNB998135151A CN99813515A CN1162404C CN 1162404 C CN1162404 C CN 1162404C CN B998135151 A CNB998135151 A CN B998135151A CN 99813515 A CN99813515 A CN 99813515A CN 1162404 C CN1162404 C CN 1162404C
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- och
- mixture
- chlorine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
技术领域technical field
本发明提供了改进的制备用于制备被称为抗组胺剂或法呢基蛋白质转移酶(FPT)抑制剂的三环化合物的中间体的方法。尤其是,本发明的化合物可用于如美国专利4,282,233和5,151,423中公开的抗组胺剂及1997.7.3公开的PCT公开No.WO97/23478中公开的FPT抑制剂的制备。The present invention provides an improved process for the preparation of intermediates useful in the preparation of tricyclic compounds known as antihistamines or farnesyl protein transferase (FPT) inhibitors. In particular, the compounds of the present invention are useful in the preparation of antihistamines as disclosed in US Patent Nos. 4,282,233 and 5,151,423 and FPT inhibitors as disclosed in PCT Publication No. WO97/23478 published on July 3, 1997.
发明内容Contents of the invention
本发明提供了制备式(I)化合物的方法,The invention provides a method for preparing a compound of formula (I),
其中,R、R1、R2、R3和R4独立地选自H、Br、Cl、F、烷基或烷氧基,该方法包括:Wherein, R, R 1 , R 2 , R 3 and R 4 are independently selected from H, Br, Cl, F, alkyl or alkoxy, and the method includes:
(A)将式(II)化合物与脱水剂反应(A) formula (II) compound is reacted with dehydrating agent
其中,RA、RB、RC、RD和RE独立地选自H、卤素、烷基或烷氧基,R5是芳基或杂芳基,Wherein, R A , R B , R C , R D and R E are independently selected from H, halogen, alkyl or alkoxy, R is aryl or heteroaryl,
生成下式的亚胺,An imine of the formula,
以及as well as
(B)将步骤(A)中产生的亚胺水解,生成式(I)化合物。本发明也提供了下式的新中间体:(B) hydrolyzing the imine produced in step (A) to generate the compound of formula (I). The present invention also provides novel intermediates of the following formula:
其中,RA、RB、RC、RD和RE独立地选自H、卤素、烷基或烷氧基,R5是芳基或杂芳基。Wherein, R A , R B , R C , R D and RE are independently selected from H, halogen, alkyl or alkoxy, and R 5 is aryl or heteroaryl.
本发明还提供了制备式(III)化合物的方法:The present invention also provides a method for preparing the compound of formula (III):
包括:include:
在钯催化剂、CO、碱及选自乙二醇二甲醚(即CH3OCH2CH2OCH3)、2-甲氧基乙基醚(即CH3OCH2CH2OCH2CH2OCH3)和三甘醇二甲醚(即CH3OCH2CH2OCH2CH2OCH2CH2OCH3)的醚存在下,使式(IV)化合物与NH2R5反应:In the palladium catalyst, CO, base and selected from ethylene glycol dimethyl ether (ie CH 3 OCH 2 CH 2 OCH 3 ), 2-methoxyethyl ether (ie CH 3 OCH 2 CH 2 OCH 2 CH 2 OCH 3 ) and triglyme (ie CH 3 OCH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 OCH 3 ) ether, the compound of formula (IV) is reacted with NH 2 R 5 :
其中X是H、Br、Cl或F,R5是芳基或杂芳基。Wherein X is H, Br, Cl or F, and R is aryl or heteroaryl.
在强碱存在下,式(III)化合物可以与具有以下结构式的化合物反应生成其中RA是Br、Cl或F的式(II)化合物,In the presence of a strong base, a compound of formula (III) can react with a compound of the following structural formula to generate a compound of formula (II) wherein RA is Br, Cl or F,
其中U是Br或Cl,RB、RC、RD和RE如上文所定义的。wherein U is Br or Cl, RB , RC , RD and RE are as defined above.
此处所用的术语“烷基”指1至6个碳原子的直链或支链烃链。The term "alkyl" as used herein refers to a straight or branched hydrocarbon chain of 1 to 6 carbon atoms.
“卤素”指氟、氯、溴或碘。"Halogen" means fluorine, chlorine, bromine or iodine.
“芳基”指苯基、苄基或多芳香环(如萘基),它们各可以任选被1至3个独立地选自C1至C6烷基、C1至C6烷氧基和卤素的取代基取代。"Aryl" refers to phenyl, benzyl or polyaromatic rings (such as naphthyl), each of which can be optionally replaced by 1 to 3 independently selected from C 1 to C 6 alkyl, C 1 to C 6 alkoxy and halogen substituents.
“杂芳基”指含有1或2个氮原子的5或6元芳环,例如,吡啶基、嘧啶基、咪唑基或吡咯基。"Heteroaryl" refers to a 5- or 6-membered aromatic ring containing 1 or 2 nitrogen atoms, eg, pyridyl, pyrimidinyl, imidazolyl or pyrrolyl.
“Ac”指乙酰基。"Ac" means acetyl.
“Et”指乙基。"Et" means ethyl.
“Ph”指苯基。"Ph" means phenyl.
本方法是制备式(I)的三环酮的现有技术方法的重大改进。例如,U.S.4,731,447公开了下面的方法:The present process is a significant improvement over prior art processes for the preparation of tricyclic ketones of formula (I). For example, U.S. 4,731,447 discloses the following method:
在此方法中,在进行下一步(弗瑞德-克来福特环化)之前,必须将从水解步骤得到的产物分离和纯化,而与此方法相比较,本发明制备式(I)化合物的方法提供可以一釜完成的更简单的合成方法。In this method, before carrying out the next step (Friedel-Crafts cyclization), the product obtained from the hydrolysis step must be separated and purified, and compared with this method, the present invention prepares formula (I) compound The method provides a simpler synthesis that can be done in one pot.
1996.10.10公开的PCT公开WO96/31478公开了下述方法:PCT publication WO96/31478 published on October 10, 1996 discloses the following method:
A,B=H,卤或C1-C6烷基A, B=H, halogen or C 1 -C 6 alkyl
在此方法中,叔丁基取代的化合物与POCl3在甲苯中于回流下反应生成腈,腈与CF3SO3H反应生成亚胺,亚胺水解生成酮。因为在腈与CF3SO3H反应之前,必须将腈分离和纯化,所以此法是两釜反应,而与此法相比较,本发明方法可以一釜完成。In this method, a tert-butyl-substituted compound is reacted with POCl 3 in toluene at reflux to form a nitrile, which is reacted with CF 3 SO 3 H to form an imine, which is hydrolyzed to form a ketone. Because the nitrile must be separated and purified before the nitrile reacts with CF 3 SO 3 H, so this method is a two-pot reaction, and compared with this method, the method of the present invention can be completed in one pot.
本方法制备的化合物可用作PCT公开No.WO97/23478和美国专利5,151,423描述的过程中的中间体以制备需要的、哌啶环的氮是被取代的化合物。使用这些过程,本发明的化合物与具有以下结构式的取代的哌啶反应:Compounds prepared by this method are useful as intermediates in the processes described in PCT Publication No. WO97/23478 and US Patent 5,151,423 to prepare the desired compounds in which the nitrogen of the piperidine ring is substituted. Using these procedures, compounds of the invention are reacted with substituted piperidines of the formula:
其中L1是选自Cl和Br的离去基团,wherein L is a leaving group selected from Cl and Br,
生成了以下结构式的化合物:Compounds of the formula:
将此化合物转化为亚哌啶基,使氮脱保护,将化合物还原为吡啶基形式。可以将吡啶基的氮与各种化合物例如酰基化合物如酯或酰氯反应生成所要的酰胺。Conversion of this compound to the piperidinylene and deprotection of the nitrogen reduces the compound to the pyridinyl form. The pyridyl nitrogen can be reacted with various compounds such as acyl compounds such as esters or acid chlorides to form the desired amides.
另外,当需要手性FPT抑制剂如PCT公开No.WO97/23478中描述的那些时,用Zn和2当量溶于醋酸酐中的三氟乙酸处理以除去羰基氧,可以将本方法制得的化合物还原。然后可以将还原的化合物与约3.5当量的二异丙基氨基锂、约1.3当量的奎宁或下式化合物、约1.2当量的4-甲磺酰基-N-叔丁氧羰基-哌啶和约1.1当量的水在甲苯中反应,Alternatively, when a chiral FPT inhibitor such as those described in PCT Publication No. WO97/23478 is desired, the carbonyl oxygen can be removed by treatment with Zn and 2 equivalents of trifluoroacetic acid in acetic anhydride, and the present method can be converted to compound reduction. The reduced compound can then be combined with about 3.5 equivalents of lithium diisopropylamide, about 1.3 equivalents of quinine or a compound of the formula, about 1.2 equivalents of 4-methylsulfonyl-N-tert-butoxycarbonyl-piperidine and about 1.1 equivalent of water reacted in toluene,
生成如下的手性化合物:The following chiral compounds are generated:
然后,可以用酸(如硫酸)处理将手性化合物脱保护,与适合的酸(如N-乙酰基-L-苯基丙氨酸)反应生成稳定的盐,接着,可以用需要的酰基基团将稳定的盐酰化。The chiral compound can then be deprotected by treatment with an acid such as sulfuric acid and reacted with a suitable acid such as N-acetyl-L-phenylalanine to form a stable salt, which can then be replaced with the desired acyl group groups will acylate stable salts.
可以利用本领域公知的方法将式(I)的化合物转化为其它式(I)的化合物,即其中R、R1、R2、R3或R4是氢的化合物可以转化为相应的其中R、R1、R2、R3或R4是卤素的化合物。WO97/23478中给出了这样的方法步骤,其中,例如,将其中R2是氯,R1、R3及R4是氢和吡啶基的氮用-COOCH2CH3基团保护的化合物与KNO3反应,将得到的硝基取代的化合物还原为胺,得到的化合物与Br2反应,并除去氨基基团,获得了其中R2是氯,R4是溴及R1和R3是氢的化合物。Compounds of formula (I) can be converted to other compounds of formula (I) using methods well known in the art, i.e. compounds wherein R, R 1 , R 2 , R 3 or R 4 are hydrogen can be converted to the corresponding compounds wherein R , R 1 , R 2 , R 3 or R 4 are halogen compounds. A process step is given in WO 97/23478 in which, for example, a compound wherein R 2 is chlorine, R 1 , R 3 and R 4 are hydrogen and pyridyl nitrogen protected with a -COOCH 2 CH 3 group is combined with KNO3 reaction, the resulting nitro-substituted compound is reduced to an amine, the resulting compound is reacted with Br2 , and the amino group is removed to obtain a compound in which R2 is chlorine, R4 is bromine and R1 and R3 are hydrogen compound of.
优选的式(I)化合物是其中R2为氯、溴或氟、更优选为氯或溴、最优选为氯的化合物。另一组优选的化合物是其中R、R1、R3和R4独立地为氢及R2为氯、溴或氟、更优选为氯或溴、最优选为氯的化合物。还有另外一组优选的化合物为其中R1、R3及R4独立地是氢及R和R2独立地选自氯、溴和氟、更优选选自氯和溴、最优选R是溴而R2是氯的化合物。还有另外一组优选的化合物为其中R1和R3独立地是氢及R、R2和R4独立地选自氯、溴和氟、更优选选自氯和溴、最优选R是溴、R2是氯和R4是溴的化合物。可以从具有相应位置的卤素取代基的式(II)的化合物制备这些优选的化合物。本领域的技术人员应当理解,当式(II)化合物具有碘取代基时,在实施本方法时,那些碘取代基会被氢取代掉。Preferred compounds of formula (I) are those wherein R2 is chlorine, bromine or fluorine, more preferably chlorine or bromine, most preferably chlorine. Another preferred group of compounds are those wherein R, R1 , R3 and R4 are independently hydrogen and R2 is chlorine, bromine or fluorine, more preferably chlorine or bromine, most preferably chlorine. Yet another group of preferred compounds is that wherein R1 , R3 and R4 are independently hydrogen and R and R2 are independently selected from chlorine, bromine and fluorine, more preferably selected from chlorine and bromine, most preferably R is bromine and R2 is a compound of chlorine. Yet another group of preferred compounds is that wherein R and R are independently hydrogen and R , R and R are independently selected from chlorine, bromine and fluorine, more preferably selected from chlorine and bromine, most preferably R is bromine , R 2 is chlorine and R 4 is a compound of bromine. These preferred compounds can be prepared from compounds of formula (II) having halogen substituents at the corresponding positions. It will be appreciated by those skilled in the art that when the compound of formula (II) has iodine substituents, those iodine substituents will be replaced by hydrogen when the method is carried out.
R5优选芳基,最优选苯基、4-甲氧基苯基、4-氯苯基或3-氯苯基。 R5 is preferably aryl, most preferably phenyl, 4-methoxyphenyl, 4-chlorophenyl or 3-chlorophenyl.
脱水剂优选选自P2O5、P2O3、P2O3Cl4、POCl3、PCl3、PCl5、C6H6P(O)Cl2(苯基膦酰二氯)、PBr3、PBr5、SOCl2、SOBr2、COCl2、H2SO4、过酸或过酸酐,脱水剂更优选选自P2O5、P2O3Cl4、PBr3、PCl5、POCl3、C6H6P(O)Cl2、(CF3SO2)2O和(CF3CF2SO2)2O。The dehydrating agent is preferably selected from P 2 O 5 , P 2 O 3 , P 2 O 3 Cl 4 , POCl 3 , PCl 3 , PCl 5 , C 6 H 6 P(O)Cl 2 (phenylphosphonic dichloride), PBr 3 , PBr 5 , SOCl 2 , SOBr 2 , COCl 2 , H 2 SO 4 , peracid or peracid anhydride, the dehydrating agent is more preferably selected from P 2 O 5 , P 2 O 3 Cl 4 , PBr 3 , PCl 5 , POCl 3 , C 6 H 6 P(O)Cl 2 , (CF 3 SO 2 ) 2 O, and (CF 3 CF 2 SO 2 ) 2 O.
优选通过将式(II)化合物和脱水剂的反应混合物与选自路易斯酸或过酸的另外的试剂接触进行本方法的步骤(A)。非限定的路易斯酸的例子包括AlCl3、FeCl3、ZnCl2、AlBr3、ZnBr2、TiCl4和SnCl4。前述的路易斯酸中,特别优选AlCl3、ZnCl2、FeCl3、SnCl4和ZnBr2。非限定的过酸的例子包括CF3SO3H、Step (A) of the process is preferably carried out by contacting a reaction mixture of a compound of formula (II) and a dehydrating agent with a further agent selected from Lewis acids or peracids. Non-limiting examples of Lewis acids include AlCl3 , FeCl3 , ZnCl2 , AlBr3 , ZnBr2 , TiCl4 , and SnCl4 . Among the aforementioned Lewis acids, AlCl 3 , ZnCl 2 , FeCl 3 , SnCl 4 and ZnBr 2 are particularly preferred. Non-limiting examples of peracids include CF3SO3H ,
和HF/BF3。前述的过酸中,特别优选CF3SO3H。可以在脱水剂与式(II)化合物反应之前、同时或之后加入路易斯酸或过酸来完成与路易斯酸或过酸的接触。特别优选的脱水剂和路易斯酸或过酸的组合包括P2O5/CF3SO3H、PCl5/AlCl3、POCl3/ZnCl2、PCl5/FeCl3、PCl5/SnCl4及POCl3/ZnBr2。and HF/BF 3 . Among the aforementioned peracids, CF 3 SO 3 H is particularly preferred. Contacting with the Lewis acid or peracid can be accomplished by adding the Lewis acid or peracid before, simultaneously with or after the reaction of the dehydrating agent with the compound of formula (II). Particularly preferred combinations of dehydrating agents and Lewis acids or peracids include P 2 O 5 /CF 3 SO 3 H, PCl 5 /AlCl 3 , POCl 3 /ZnCl 2 , PCl 5 /FeCl 3 , PCl 5 /SnCl 4 and POCl 3 /ZnBr 2 .
当步骤(A)使用除酐以外的脱水剂时,脱水剂的用量优选1至20当量,更优选1至10当量,最优选1.0至8.0当量。当利用过酸酐作脱水剂时,脱水剂的用量优选0.5至10当量,更优选1.0至5.0当量,最优选1.2至2.0当量。当除了使用脱水剂之外还使用路易斯酸时,路易斯酸的用量优选1至20当量,更优选1.5至10当量,最优选2至5当量。当除了使用脱水剂之外还使用过酸时,过酸的用量优选0.5至10当量,更优选1至5当量,最优选2至4当量。When step (A) uses a dehydrating agent other than an anhydride, the amount of the dehydrating agent used is preferably 1 to 20 equivalents, more preferably 1 to 10 equivalents, most preferably 1.0 to 8.0 equivalents. When peracid anhydride is used as the dehydrating agent, the amount of the dehydrating agent is preferably 0.5 to 10 equivalents, more preferably 1.0 to 5.0 equivalents, most preferably 1.2 to 2.0 equivalents. When a Lewis acid is used in addition to the dehydrating agent, the Lewis acid is used in an amount of preferably 1 to 20 equivalents, more preferably 1.5 to 10 equivalents, most preferably 2 to 5 equivalents. When a peracid is used in addition to the dehydrating agent, the peracid is used in an amount of preferably 0.5 to 10 equivalents, more preferably 1 to 5 equivalents, most preferably 2 to 4 equivalents.
优选在温度为10至120℃、更优选15至90℃、最优选20至90℃下进行步骤(A)。反应时间为1至60小时,优选2至40小时,最优选5至35小时。Step (A) is preferably carried out at a temperature of from 10 to 120°C, more preferably from 15 to 90°C, most preferably from 20 to 90°C. The reaction time is 1 to 60 hours, preferably 2 to 40 hours, most preferably 5 to 35 hours.
优选加水使步骤(A)中生成的亚胺水解,优选水用量为1至10倍体积的式(II)的酰胺,更优选1.5至7倍体积,最优选2至5倍体积。优选在温度为20至120℃、更优选30至100℃、最优选40至80℃下进行水解。It is preferred to add water to hydrolyze the imine generated in step (A), the preferred amount of water is 1 to 10 times the volume of the amide of formula (II), more preferably 1.5 to 7 times the volume, most preferably 2 to 5 times the volume. The hydrolysis is preferably carried out at a temperature of from 20 to 120°C, more preferably from 30 to 100°C, most preferably from 40 to 80°C.
优选在质子惰性的有机溶剂中进行步骤(A)和(B)。质子惰性的有机溶剂优选选自二氯乙烷、二氯甲烷、苯和卤代的芳香族溶剂如氯苯、二氯苯、三氯苯和三氟甲基苯。Preference is given to carrying out steps (A) and (B) in an aprotic organic solvent. The aprotic organic solvent is preferably selected from dichloroethane, dichloromethane, benzene and halogenated aromatic solvents such as chlorobenzene, dichlorobenzene, trichlorobenzene and trifluoromethylbenzene.
可以以下述的方案制备式(II)的起始化合物:The starting compound of formula (II) can be prepared in the following scheme:
如上述方案所示(其中RA、RB、RC、RD、RE和R5如上文所定义),在钯催化剂(如Pd(OAc)2/联吡啶或(Ph3P)2PdCl2)、一氧化碳和碱存在下,在合适的溶剂(如四氢呋喃(“THF”)、二甲基甲酰胺(“DMF”)、乙腈(CH3CN)和甲苯或其结合,最优选乙腈(CH3CN))中吡啶化合物 1与NH2R5反应生成酰胺化合物 2,其中反应温度为约35至100℃,优选为约55℃,反应压力为约5至500psi,优选为约50至150psi。非限定性的适合于前述反应的碱的例子包括C1至C10烷基胺,如三乙胺,三正丁胺和1,8-二氮杂双环[5.4.0]十一烯-7(“DBU”),和无机碱如K2CO3、Na2CO3、Na2HPO4和NaOH。碱优选选自K2CO3、DBU和三乙胺,DBU优选与Pd(OAc)2/联吡啶一起使用,三乙胺优选与(Ph3P)2PdCl2一起使用。在强碱(如二异丙基氨基锂(“LDA”)、正丁基锂、六甲基二甲硅烷基氨基锂或氨基钠,优选LDA或正丁基锂)存在下、在合适的溶剂如THF中、在约-50至-20℃、优选约-30至-20℃的温度下使酰胺化合物 2与化合物 3反应生成式(II)化合物。As shown in the above scheme (where R A , R B , R C , R D , RE and R 5 are as defined above), in a palladium catalyst (such as Pd(OAc) 2 /bipyridine or (Ph 3 P) 2 PdCl 2 ), carbon monoxide and a base, in a suitable solvent such as tetrahydrofuran (“THF”), dimethylformamide (“DMF”), acetonitrile (CH 3 CN) and toluene or combinations thereof, most preferably acetonitrile ( CH 3 CN)) reacts pyridine compound 1 with NH 2 R 5 to generate amide compound 2 , wherein the reaction temperature is about 35 to 100°C, preferably about 55°C, and the reaction pressure is about 5 to 500psi, preferably about 50 to 150psi . Non-limiting examples of bases suitable for the foregoing reactions include C1 to C10 alkylamines such as triethylamine, tri-n-butylamine and 1,8-diazabicyclo[5.4.0]undecene-7 ("DBU"), and inorganic bases such as K2CO3 , Na2CO3 , Na2HPO4 , and NaOH . The base is preferably selected from K 2 CO 3 , DBU and triethylamine, DBU is preferably used with Pd(OAc) 2 /bipyridyl, triethylamine is preferably used with (Ph 3 P) 2 PdCl 2 . In the presence of a strong base such as lithium diisopropylamide ("LDA"), n-butyllithium, lithium hexamethyldisilylamide or sodium amide, preferably LDA or n-butyllithium, in a suitable solvent Amide compound 2 is reacted with compound 3 , eg, in THF, at a temperature of about -50 to -20°C, preferably about -30 to -20°C to form the compound of formula (II).
也可以选择如下所示的方案制备酰胺化合物 2:It is also possible to choose the scheme shown below to prepare amide compound 2 :
在合适的溶剂如二氯甲烷中,于约-30至0℃下,吡啶羧酸化合物 4与有机碱如三乙胺反应,接着与酰氯如新戊酰氯或氯甲酸酯如C2H5OCOCl反应,生成混合酐。将纯的或溶于合适的溶剂中的NH2R5于-30℃至0℃下加入混合物中生成酰胺化合物 2。Pyridinecarboxylic acid compound 4 is reacted with an organic base such as triethylamine followed by an acid chloride such as pivaloyl chloride or a chloroformate such as C2H5 in a suitable solvent such as dichloromethane at about -30 to 0 °C. OCOCl reacts to form mixed anhydrides. NH2R5 , neat or dissolved in a suitable solvent, is added to the mixture at -30°C to 0°C to generate amide compound 2 .
在钯催化剂、一氧化碳、碱及选自乙二醇二甲醚(即CH3OCH2CH2OCH3)、2-甲氧基乙基醚(即CH3OCH2CH2OCH2CH2OCH3)和三甘醇二甲醚(即CH3OCH2CH2OCH2CH2OCH2CH2OCH3)的醚存在下,式(IV)化合物与NH2R5反应制备式(III)化合物。X优选为Br、C1或F,最优选为Br,R5优选为苯基、4-甲氧基苯基、4-氯苯基或3-氯苯基。本方法可使用的钯催化剂的非限定的例子包括Pd(OAc)2、PdCl2、(PPh3)2PdCl2、PdBr2和(PPh3)4Pd,特别优选Pd(OAc)2和PdCl2。本方法在约35至120℃、优选约40至100℃、最优选约45至90℃的温度和约5至500psi、优选约30至150psi、最优选约40至100psi的压力下进行。适合于前述反应的非限定的碱的例子包括C1至C10烷基胺,如二异丙基乙胺、二异丙基苄基胺、三正丁胺、三异丙胺、三乙胺、叔丁胺和1,8-二氮杂双环[5.4.0]十一烯-7(“DBU”),和无机碱如K2CO3、KHCO3、Na2CO3、NaHCO3、Na3PO4、Na2HPO4和NaOH。碱优选选自K2CO3、DBU、三乙胺和二异丙基乙胺,最优选选自DBU和二异丙基乙胺。除了乙二醇二甲醚、2-甲氧基乙基醚或三甘醇二甲醚以外本方法优选还在溶剂中进行。非限定的合适的溶剂的例子包括甲苯、二氯苯、乙腈、三氟甲基苯、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、四氢呋喃和二甲苯,特别优选甲苯和氯苯。因为乙二醇二甲醚、2-甲氧基乙基醚或三甘醇二甲醚作为钯催化剂的配体,所以本方法可以在不用联吡啶作为配体的情况下实施。NH2R5的用量优选为0.9至5当量,更优选为1.0至3当量,最优选为1.1至1.5当量。碱的用量优选为0.8至10当量,更优选为1.0至5当量,最优选为1.2至2.0当量。乙二醇二甲醚、2-甲氧基乙基醚或三甘醇二甲醚的用量优选为0.2至5.0倍体积所用的2,5-二溴-3-甲基吡啶,更优选为0.4至2.0倍体积,最优选为0.5至1.5倍体积。其它溶剂(如甲苯或氯苯)的量优选为1.0至20倍体积所用的2,5-二溴-3-甲基吡啶,更优选为1.5至10倍体积,最优选为2至5倍体积。In the palladium catalyst, carbon monoxide, alkali and selected from ethylene glycol dimethyl ether (ie CH 3 OCH 2 CH 2 OCH 3 ), 2-methoxyethyl ether (ie CH 3 OCH 2 CH 2 OCH 2 CH 2 OCH 3 ) and triglyme (ie CH 3 OCH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 OCH 3 ) in the presence of the ether, the compound of formula (IV) reacts with NH 2 R 5 to prepare the compound of formula (III). X is preferably Br, Cl or F, most preferably Br, and R is preferably phenyl, 4-methoxyphenyl, 4-chlorophenyl or 3-chlorophenyl. Non-limiting examples of palladium catalysts that can be used in the process include Pd(OAc) 2 , PdCl 2 , (PPh 3 ) 2 PdCl 2 , PdBr 2 and (PPh 3 ) 4 Pd, with Pd(OAc) 2 and PdCl 2 being particularly preferred. . The process is carried out at a temperature of about 35 to 120°C, preferably about 40 to 100°C, most preferably about 45 to 90°C and a pressure of about 5 to 500 psi, preferably about 30 to 150 psi, most preferably about 40 to 100 psi. Non-limiting examples of bases suitable for the foregoing reactions include C1 to C10 alkylamines such as diisopropylethylamine, diisopropylbenzylamine, tri-n-butylamine, triisopropylamine, triethylamine, tert-butylamine and 1,8-diazabicyclo[5.4.0]undecene-7 (“DBU”), and inorganic bases such as K 2 CO 3 , KHCO 3 , Na 2 CO 3 , NaHCO 3 , Na 3 PO 4 , Na 2 HPO 4 and NaOH. The base is preferably selected from K2CO3 , DBU, triethylamine and diisopropylethylamine, most preferably from DBU and diisopropylethylamine. The process is preferably carried out in solvents other than ethylene glycol dimethyl ether, 2-methoxyethyl ether or triglyme. Non-limiting examples of suitable solvents include toluene, dichlorobenzene, acetonitrile, trifluoromethylbenzene, N,N-dimethylformamide, N,N-dimethylacetamide, tetrahydrofuran and xylene, particularly preferably Toluene and Chlorobenzene. Since ethylene glycol dimethyl ether, 2-methoxyethyl ether or triglyme acts as a ligand for the palladium catalyst, the process can be carried out without bipyridine as a ligand. The amount of NH 2 R 5 used is preferably 0.9 to 5 equivalents, more preferably 1.0 to 3 equivalents, most preferably 1.1 to 1.5 equivalents. The amount of the base used is preferably 0.8 to 10 equivalents, more preferably 1.0 to 5 equivalents, most preferably 1.2 to 2.0 equivalents. The amount of ethylene glycol dimethyl ether, 2-methoxyethyl ether or triglyme is preferably 0.2 to 5.0 times the volume of 2,5-dibromo-3-methylpyridine used, more preferably 0.4 to 2.0 volumes, most preferably 0.5 to 1.5 volumes. The amount of other solvents (such as toluene or chlorobenzene) is preferably 1.0 to 20 times the volume of 2,5-dibromo-3-picoline used, more preferably 1.5 to 10 times the volume, most preferably 2 to 5 times the volume .
前述方法中所用的起始原料即化合物 1、NH2R5、化合物 3和化合物 4是本领域公知的或本领域的技术人员可以很容易地制得。The starting materials used in the aforementioned methods, namely compound 1 , NH 2 R 5 , compound 3 and compound 4 are well known in the art or can be easily prepared by those skilled in the art.
下述实施例具体说明上述发明,但这些实施例并不构成对本发明范围的限定。对本领域的技术人员来说本发明范围内的其它试剂和类似方法是显而易见的。The following examples illustrate the above-mentioned invention in detail, but these examples are not intended to limit the scope of the invention. Other reagents and analogous methods within the scope of the invention will be apparent to those skilled in the art.
具体实施方式Detailed ways
实施例A Example A
将250g(949mmol)2,5-二溴-3-甲基吡啶、4.5g(20mmol)Pd(OAc)2、127mL(1.1mol)苯胺、210mL(1.4mol)1,8-二氮杂双环[5.4.0]十一烯-7、500mL甲苯和250mL乙二醇二甲醚连续地加入4升的高压釜中。将高压釜密封、抽空、用氮气吹扫,充入一氧化碳至80psi。将反应混合物加热到65℃,如果必要,周期性地充一氧化碳,保温约2天,然后冷却至室温。在抽真空、氮气吹扫条件下,将高压釜中的物料排出,借助于水和甲苯将物料转移到10升的烧瓶中。将25克活性炭(Darco)和25克硅藻土(Supercel)加入混合物中。通过硅藻土(Celite)垫过滤物料,用甲苯洗涤物料。用2×1升的甲苯萃取滤出液。用盐水洗涤合并的萃取液,将其浓缩至750ml。用异丙醇(i-PrOH)除去残留的甲苯。将滤渣从热异丙醇(i-PrOH)中再结晶,将沉淀物过滤。用异丙醇洗涤,在50℃下干燥,得到220克(76%)的白色固体酰胺。250g (949mmol) 2,5-dibromo-3-picoline, 4.5g (20mmol) Pd(OAc) 2 , 127mL (1.1mol) aniline, 210mL (1.4mol) 1,8-diazabicyclo[ 5.4.0] Undecene-7, 500 mL of toluene and 250 mL of ethylene glycol dimethyl ether were continuously added into a 4-liter autoclave. The autoclave was sealed, evacuated, purged with nitrogen, and charged with carbon monoxide to 80 psi. The reaction mixture was heated to 65°C, periodically filled with carbon monoxide, if necessary, kept at this temperature for about 2 days, and then cooled to room temperature. Under vacuum and nitrogen purge, the contents of the autoclave were drained and transferred to a 10-liter flask with the aid of water and toluene. 25 grams of activated charcoal (Darco) and 25 grams of diatomaceous earth (Supercel) were added to the mixture. Filter the material through a pad of Celite, washing the material with toluene. The filtrate was extracted with 2 x 1 liter of toluene. The combined extracts were washed with brine and concentrated to 750ml. Residual toluene was removed with isopropanol (i-PrOH). The filter residue was recrystallized from hot isopropanol (i-PrOH) and the precipitate was filtered. Washing with isopropanol and drying at 50°C yielded 220 g (76%) of the amide as a white solid.
制备1 preparation 1
将400g(2.21mol)2-溴-3-甲基吡啶、8.2g(12mmol)(Ph3P)2PdCl2、1.0L乙腈、295g(3.16mol)苯胺和515g(3.38mmol)DBU连续地加入4升的高压釜中。将高压釜密封、抽空、用氮气吹扫,充一氧化碳至80psi。将反应混合物加热到65℃,如果必要,周期性地充一氧化碳,保温9小时,然后冷却到室温。在抽真空和氮气吹扫下,将高压釜中的物料排出,借助于水和乙腈将物料转移到分液漏斗中。将40克活性炭(Darco)和40克硅藻土(Supercel)加入混合物中。将物料搅拌30分钟,过滤,用乙腈洗涤。将滤出液浓缩至最终为1.6升。加3.0升水使黄色固体的产品沉淀。将固体过滤、干燥,得到427克(90%)的酰胺。Mp.66-67℃。1H NMR(CDCl3):δ10.23(bs,1H),8.37(dd,J=4.6Hz,0.8Hz,1H),7.71(m,2H),7.62(dd,J=6.95Hz,1H),7.31-7.36(m,3H),7.10(t,J=7.42Hz,1H),2.79(s,3H)。13CNMR(CDCl3):δ163.52,146.70,145.21,141.28,138.02,136.13,128.94,125.95,123.97,119.62,20.80。IR:3330(w),2920(s),1680(m)em-1。C13H12N2O的分析计算值:C,73.58,H,5.66,N,13.21;实测值:C,73.29,H,5.76,N,12.81。400 g (2.21 mol) of 2-bromo-3-picoline, 8.2 g (12 mmol) of (Ph 3 P) 2 PdCl 2 , 1.0 L of acetonitrile, 295 g (3.16 mol) of aniline and 515 g (3.38 mmol) of DBU were added continuously 4 liter autoclave. The autoclave was sealed, evacuated, purged with nitrogen, and charged to 80 psi with carbon monoxide. The reaction mixture was heated to 65°C, periodically charged with carbon monoxide, if necessary, kept at that temperature for 9 hours, and then cooled to room temperature. Under vacuum and nitrogen purge, the contents of the autoclave were vented and transferred to a separatory funnel with the aid of water and acetonitrile. 40 grams of activated charcoal (Darco) and 40 grams of diatomaceous earth (Supercel) were added to the mixture. The material was stirred for 30 minutes, filtered and washed with acetonitrile. The filtrate was concentrated to a final volume of 1.6 liters. 3.0 liters of water were added to precipitate the product as a yellow solid. The solid was filtered and dried to yield 427 g (90%) of the amide. Mp.66-67°C. 1 H NMR (CDCl 3 ): δ10.23 (bs, 1H), 8.37 (dd, J=4.6Hz, 0.8Hz, 1H), 7.71 (m, 2H), 7.62 (dd, J=6.95Hz, 1H) , 7.31-7.36 (m, 3H), 7.10 (t, J=7.42Hz, 1H), 2.79 (s, 3H). 13 CNMR (CDCl 3 ): δ163.52, 146.70, 145.21, 141.28, 138.02, 136.13, 128.94, 125.95, 123.97, 119.62, 20.80. IR: 3330(w), 2920(s), 1680(m) em -1 . Anal . Calcd. for C13H12N2O : C, 73.58, H, 5.66, N , 13.21; Found: C, 73.29, H, 5.76, N, 12.81.
制备2 preparation 2
将1.5M二异丙基氨基锂单(四氢呋喃)的溶液(225mL,0.336mol)以滴加方式加入-25℃的溶于THF(400mL)和二异丙胺(7.05mL,0.050mol)的酰胺1(50g,0.168mol)溶液中。将得到的二价阴离子溶液在-20至-25℃下老化1小时,用3-氯苄基氯(22.0mL,0.176mol)将其骤冷。允许混合物温热至0℃,1小时之后,在饱和氯化铵水溶液中骤冷。进行相分离,用叔丁基甲基醚(350mL)萃取水层。用盐溶液洗涤合并的有机溶液,将其浓缩至油状物。然后将产物在异丙醇(200mL)中结晶,得到62.7克(89.8%)偶合产物。Mp.102-103℃。1H NMR(CDCl3):δ10.07(s,1H),8.56(d,J=2.1Hz,1H),7.77(dd,J=8.7Hz,1.1Hz,2H),7.70(d,J=2.1Hz,1H),7.42(t,J=8.4Hz,2H),7.28(d,J=2.4Hz,1H),7.16-7.25(m,4H),3.49-3.53(m,2H),2.99-3.03(m,2H)。13C NMR(CDCl3):δ162.45,146.85,145.17,143.16,142.95,140.95,137.70,134.10,129.63,129.06,128.74,126.90,126.33,124.36,123.24,119.84,36.91,35.35。IR:2930(s),1690(m)cm-1。C20H16BrClN2O的分析计算:C,57.83,H,3.85,N,6.75;实测值:C,58.05,H,4.06,N,6.80。A 1.5M solution of lithium diisopropylamide mono(tetrahydrofuran) (225 mL, 0.336 mol) was added dropwise to amide 1 dissolved in THF (400 mL) and diisopropylamine (7.05 mL, 0.050 mol) at -25°C (50g, 0.168mol) solution. The resulting dianion solution was aged at -20 to -25°C for 1 hour and quenched with 3-chlorobenzyl chloride (22.0 mL, 0.176 mol). The mixture was allowed to warm to 0 °C and after 1 h, was quenched in saturated aqueous ammonium chloride. The phases were separated and the aqueous layer was extracted with tert-butyl methyl ether (350 mL). The combined organic solutions were washed with brine solution and concentrated to an oil. The product was then crystallized from isopropanol (200 mL) to yield 62.7 g (89.8%) of the coupled product. Mp.102-103°C. 1 H NMR (CDCl 3 ): δ10.07(s, 1H), 8.56(d, J=2.1Hz, 1H), 7.77(dd, J=8.7Hz, 1.1Hz, 2H), 7.70(d, J= 2.1Hz, 1H), 7.42(t, J=8.4Hz, 2H), 7.28(d, J=2.4Hz, 1H), 7.16-7.25(m, 4H), 3.49-3.53(m, 2H), 2.99- 3.03 (m, 2H). 13 C NMR (CDCl 3 ): δ162.45, 146.85, 145.17, 143.16, 142.95, 140.95, 137.70, 134.10, 129.63, 129.06, 128.74, 126.90, 126.33, 124.36, 123.24, 136.95, 126.90, 126.33, 124.36, 123.24, 136.95, IR: 2930(s), 1690(m) cm -1 . Anal. Calcd. for C20H16BrClN2O : C, 57.83, H, 3.85, N , 6.75; Found: C, 58.05, H, 4.06, N, 6.80.
制备3 preparation 3
将2.5M丁基锂溶于己烷的溶液(185mL,0.462mol)以滴加方式加入-25℃溶于THF(500mL)的酰胺 2(50g,0.231mol)溶液中。将得到的二价阴离子溶液在-20至-25℃下老化1小时,用3-氯苄基氯(31.0mL,0.248mol)将其骤冷。允许混合物温热至0℃,1小时后,在饱和氯化铵水溶液中骤冷。进行相分离,用叔丁基甲基醚(350mL)萃取水层。用盐溶液洗涤合并的有机溶液,将其浓缩至油状物。然后将产物在异丙醇(200mL)中结晶,得到71.6克(91.5%)偶合产物。Mp.80-81℃。1H NMR(CDCl3):δ10.23(s,1H),8.48(dd,J=4.6Hz,1.6Hz,1H),7.78(dd,J=0.8Hz,8.4Hz,2H),7.48(dd,J=7.9Hz,1.5Hz,1H),7.39-7.12(m,8H),3.54-3.50(m,2H),3.02-2.98(m,2H)。13C NMR(CDCl3):δ164.09,147.63,146.72,144.63,141.91,140.16,138.97,134.98,130.55,130.05,129.82,128.03,127.16,127.03,125.17,120.84,38.30,36.77。IR:2930(s),1690(m)cm-1。C20H17ClN2O的分析计算:C,71.43,H,5.06,N,8.33;实测值:C,71.37,H,5.12,N,8.35。A solution of 2.5M butyl lithium in hexane (185 mL, 0.462 mol) was added dropwise to a solution of amide 2 (50 g, 0.231 mol) in THF (500 mL) at -25°C. The resulting dianion solution was aged at -20 to -25°C for 1 hour and quenched with 3-chlorobenzyl chloride (31.0 mL, 0.248 mol). The mixture was allowed to warm to 0°C and, after 1 hour, was quenched in saturated aqueous ammonium chloride. The phases were separated and the aqueous layer was extracted with tert-butyl methyl ether (350 mL). The combined organic solutions were washed with brine solution and concentrated to an oil. The product was then crystallized from isopropanol (200 mL) to yield 71.6 g (91.5%) of the coupled product. Mp.80-81°C. 1 H NMR (CDCl 3 ): δ10.23(s, 1H), 8.48(dd, J=4.6Hz, 1.6Hz, 1H), 7.78(dd, J=0.8Hz, 8.4Hz, 2H), 7.48(dd , J=7.9Hz, 1.5Hz, 1H), 7.39-7.12(m, 8H), 3.54-3.50(m, 2H), 3.02-2.98(m, 2H). 13 C NMR (CDCl 3 ): δ164.09, 147.63, 146.72, 144.63, 141.91, 140.16, 138.97, 134.98, 130.55, 130.05, 129.82, 128.03, 127.16, 127.03, 125.17, 320.84, IR: 2930(s), 1690(m) cm -1 . Anal. Calcd. for C20H17ClN2O : C , 71.43, H, 5.06, N, 8.33; Found: C, 71.37, H, 5.12, N, 8.35.
实施例1 Example 1
将100g(241mmol)酰胺 3、137g(963mmol)P2O5及700mL氯苯加入装配了机械搅拌器、温度计和加液漏斗的烘干的3升三颈烧瓶中。将64.2mL(722mmol)的三氟甲磺酸滴加入上述浆液中,同时保持温度在35℃以下。将得到的混合物加热到80至85℃,在此温度下搅拌约20小时。将混合物冷却至45℃,将溶于300mL氯苯中的102g(722mmol)P2O5加入混合物中。将混合物加热到80至85℃,再在此温度下搅拌20小时。在10℃向得到的混合物中加入500mL水。将混合物加热到70℃,水解2小时。将反应混合物冷却至室温,将200mL正丁醇加入混合物中。进行相分离,用盐水、稀氢氧化钠溶液和稀盐酸溶液洗涤有机层。将有机层浓缩至300mL。加入500mLTHF和2.4当量的浓盐酸使产物沉淀。将固体物滤出,用冷的正丁醇洗涤固体物,将固体物干燥,得到61.7克(71%)的以盐酸盐存在的环状酮。在游离碱的情况下进行分析。Mp.119-120℃。1H NMR(CDCl3):δ8.66(d,J=2.0Hz,1H),7.96(d,J=8.0Hz,1H),7.75(d,J=1.5Hz,1H),7.27(dd,J=8.0Hz,2.0Hz,1H),7.18(d,J=1.0Hz,1H),3.17-3.09(m,4H)。13C NMR(CDCl3):δ192.7,153.3,150.6,143.8,140.7,140.1,139.3,136.2,133.9,130.6,128.4,124.4,35.4,33.5。IR(KBr,液体石蜡)1660,1590,1290cm-1。C14H9BrClNO的分析计算值:C,52.11,H,2.80,N,4.34,Br,24.80,Cl,11.00;实测值:C,52.03,H,2.82,N,4.38,Br,24.95,Cl,10.09。100 g (241 mmol) of amide 3 , 137 g (963 mmol) of P 2 O 5 and 700 mL of chlorobenzene were added to an oven-dried 3-liter three-necked flask equipped with a mechanical stirrer, thermometer and addition funnel. 64.2 mL (722 mmol) of trifluoromethanesulfonic acid was added dropwise to the above slurry while keeping the temperature below 35 °C. The resulting mixture was heated to 80 to 85°C and stirred at this temperature for about 20 hours. The mixture was cooled to 45° C., and 102 g (722 mmol) of P 2 O 5 dissolved in 300 mL of chlorobenzene was added to the mixture. The mixture was heated to 80 to 85°C and stirred at this temperature for 20 hours. To the resulting mixture was added 500 mL of water at 10°C. The mixture was heated to 70°C and hydrolyzed for 2 hours. The reaction mixture was cooled to room temperature, and 200 mL of n-butanol was added to the mixture. The phases were separated and the organic layer was washed with brine, dilute sodium hydroxide solution and dilute hydrochloric acid solution. The organic layer was concentrated to 300 mL. The product was precipitated by adding 500 mL of THF and 2.4 equivalents of concentrated hydrochloric acid. The solid was filtered off, washed with cold n-butanol and dried to yield 61.7 g (71%) of the cyclic ketone as the hydrochloride salt. The analysis was carried out in the case of free base. Mp.119-120°C. 1 H NMR (CDCl 3 ): δ8.66 (d, J=2.0Hz, 1H), 7.96 (d, J=8.0Hz, 1H), 7.75 (d, J=1.5Hz, 1H), 7.27 (dd, J=8.0Hz, 2.0Hz, 1H), 7.18(d, J=1.0Hz, 1H), 3.17-3.09(m, 4H). 13 C NMR (CDCl 3 ): δ192.7, 153.3, 150.6, 143.8, 140.7, 140.1, 139.3, 136.2, 133.9, 130.6, 128.4, 124.4, 35.4, 33.5. IR (KBr, liquid paraffin) 1660, 1590, 1290 cm -1 . Anal. Calcd. for C14H9BrClNO : C, 52.11, H, 2.80, N, 4.34, Br, 24.80, Cl, 11.00; Found: C, 52.03, H, 2.82, N, 4.38, Br, 24.95, Cl , 10.09.
实施例2 Example 2
将68.35g(481mmol)P2O5、170mL二氯乙烷及10g(24mmol)酰胺 3加入装配了机械搅拌器的烘干的250mL三颈烧瓶中。将混合物加热至55至60℃,保持16小时,得到约70%的亚胺产物,如相对于标准物用HPLC测定的。利用实施例1所述的方法步骤将亚胺水解,获得所要的三环酮。Add 68.35g (481mmol) of P 2 O 5 , 170mL of dichloroethane and 10g (24mmol) of amide 3 into an oven-dried 250mL three-necked flask equipped with a mechanical stirrer. The mixture was heated to 55 to 60°C for 16 hours to give about 70% imine product as determined by HPLC relative to standards. The imine is hydrolyzed using the procedure described in Example 1 to obtain the desired tricyclic ketone.
实施例3 Example 3
将250mL二氯乙烷、4.2g(15mmol)P2O5、2mL(12mmol)三氟甲磺酸酐及2mL(30mmol)三氟甲磺酸加入装配了机械搅拌器、温度计和加液漏斗的烘干的250mL三颈烧瓶中。将5.0g(14.9mmol)酰胺 4加入此混合物中。将混合物加热至80℃保持18小时。将混合物冷却至10℃,加入70mL水。将混合物加热到70℃,水解1小时。将反应混合物冷却至室温,用氢氧化钠将反应混合物的pH值调节到5-6。进行相分离,用叔丁基甲基醚萃取水层。用氯化铵和碳酸氢钠溶液连续地洗涤合并的有机层,将有机层浓缩得到残留物。加入叔丁基甲基醚使产物沉淀。将固体物滤出,用冷的叔丁基甲基醚洗涤固体物,将固体物干燥,得到2.4克(68.5%)黄色固体物。产物的NMR光谱与期望的环化酮的谱图一样。Add 250 mL of dichloroethane, 4.2 g (15 mmol) of P 2 O 5 , 2 mL (12 mmol) of trifluoromethanesulfonic anhydride and 2 mL (30 mmol) of trifluoromethanesulfonic acid into an oven equipped with a mechanical stirrer, a thermometer and an addition funnel. Dry 250mL three-necked flask. 5.0 g (14.9 mmol) of amide 4 were added to this mixture. The mixture was heated to 80°C for 18 hours. The mixture was cooled to 10 °C and 70 mL of water was added. The mixture was heated to 70°C and hydrolyzed for 1 hour. The reaction mixture was cooled to room temperature, and the pH of the reaction mixture was adjusted to 5-6 with sodium hydroxide. The phases were separated and the aqueous layer was extracted with tert-butyl methyl ether. The combined organic layers were washed successively with ammonium chloride and sodium bicarbonate solutions, and the organic layers were concentrated to obtain a residue. The product was precipitated by addition of tert-butyl methyl ether. The solid was filtered off, washed with cold tert-butyl methyl ether, and dried to yield 2.4 g (68.5%) of a yellow solid. The NMR spectrum of the product was identical to that of the expected cyclized ketone.
实施例4 Example 4
8-氯-5,6-二氢-11H-苯并[5,6]环庚烷并[1,2-b]吡啶-11-酮8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one
将溶于氯苯(400mL)的三氟甲磺酸(63.2mL,0.71mol)和磷酰氯(66.4mL,0.71mol)的混合物在室温下搅拌半小时。将溶于氯苯(240mL)的N-苯基-3-[2-(3-氯苯基)乙基]-2-吡啶甲酰胺 4(120g,0.36mol)溶液加入上述混合物中。将混合物加热到110℃保持18小时,随后冷却至50℃。加入400mL水,将双相混合物加热到80℃保持半小时。将混合物冷却至室温,剧烈搅拌10分钟,然后放置10分钟。通过过滤和在水(300mL)与甲苯(500mL)之间分配移走产物。用10M的氢氧化钠溶液将水相的pH值调节至10。通过减压蒸馏除去100mL有机相。将活性炭(5.5g)加入混合物中,让混合物滤过硅藻土(celite)垫。真空下,将溶液浓缩至300mL,将150mL正己烷加入混合物中。在过滤之前,将混合物冷却至0-10℃,并在此温度下搅拌1小时。用100mL冷的甲苯洗涤产物,然后将产物风干几小时。产量=44.1克(50.8%)。A mixture of trifluoromethanesulfonic acid (63.2 mL, 0.71 mol) and phosphorus oxychloride (66.4 mL, 0.71 mol) dissolved in chlorobenzene (400 mL) was stirred at room temperature for half an hour. A solution of N-phenyl-3-[2-(3-chlorophenyl)ethyl]-2-pyridinecarboxamide 4 (120 g, 0.36 mol) dissolved in chlorobenzene (240 mL) was added to the above mixture. The mixture was heated to 110°C for 18 hours, then cooled to 50°C. 400 mL of water was added and the biphasic mixture was heated to 80°C for half an hour. The mixture was cooled to room temperature, stirred vigorously for 10 minutes, and then left to stand for 10 minutes. The product was removed by filtration and partitioned between water (300 mL) and toluene (500 mL). The pH of the aqueous phase was adjusted to 10 with 10 M sodium hydroxide solution. 100 mL of the organic phase was removed by distillation under reduced pressure. Activated carbon (5.5 g) was added to the mixture and the mixture was filtered through a pad of celite. Under vacuum, the solution was concentrated to 300 mL, and 150 mL of n-hexane was added to the mixture. The mixture was cooled to 0-10°C and stirred at this temperature for 1 hour before filtration. The product was washed with 100 mL of cold toluene and then air dried for several hours. Yield = 44.1 g (50.8%).
实施例5 Example 5
8-氯-5,6-二氢-11H-苯并[5,6]环庚烷并[1,2-b]吡啶-11-酮8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one
将PCl5(95%,97.5g,0.45mol)加入溶于二氯甲烷(500mL)的N-苯基-3-[2-(3-氯苯基)乙基]-2-吡啶甲酰胺 4(100g,0.30mol)溶液中。将得到的混合物在室温下搅拌1小时。接着将AlCl3(158.5g,1.19mol)加入混合物中,随后在室温下搅拌1小时。然后将溶液倒到冰(500g)上,在将得到的混合物冷却至室温之前,将其加热回流1小时。用10M的氢氧化钠(700mL)将水相的pH值调节至14,将静止的悬浮液滤过烧结玻璃漏斗。用二氯甲烷(2×100mL)洗涤收集的固体物。分离出滤液中的有机层,用1M的盐酸(1×200+1×100mL)洗涤有机层。真空下,将有机层浓缩至油状物,加入100mL甲苯,再次将混合物在真空下浓缩。将油状物溶于甲苯(150mL),并将活性炭(3.5g)加入其中。将混合物滤过硅藻土(celite)垫,接着将己烷(100mL)加入滤液中。在过滤之前,将混合物冷却至0℃保持1小时。将收集的产物在真空烘箱中于60℃干燥过夜。产量=44.2克(61%)。PCl 5 (95%, 97.5 g, 0.45 mol) was added to N-phenyl-3-[2-(3-chlorophenyl)ethyl]-2-pyridinecarboxamide dissolved in dichloromethane (500 mL) 4 (100g, 0.30mol) solution. The resulting mixture was stirred at room temperature for 1 hour. Then AlCl 3 (158.5 g, 1.19 mol) was added to the mixture, followed by stirring at room temperature for 1 hour. The solution was then poured onto ice (500 g) and the resulting mixture was heated to reflux for 1 hour before cooling to room temperature. The pH of the aqueous phase was adjusted to 14 with 10M sodium hydroxide (700 mL), and the resting suspension was filtered through a sintered glass funnel. The collected solid was washed with dichloromethane (2 x 100 mL). The organic layer in the filtrate was separated and washed with 1M hydrochloric acid (1×200+1×100 mL). The organic layer was concentrated to an oil under vacuum, 100 mL of toluene was added, and the mixture was concentrated under vacuum again. The oil was dissolved in toluene (150 mL), and activated carbon (3.5 g) was added thereto. The mixture was filtered through a pad of celite, then hexane (100 mL) was added to the filtrate. The mixture was cooled to 0 °C for 1 hour before being filtered. The collected product was dried overnight in a vacuum oven at 60°C. Yield = 44.2 g (61%).
实施例6 Example 6
在5℃下,用20分钟将溶于二氯甲烷(60mL)的N-(4-氯苯基)-3-[2-(3-氯苯基)乙基]-2-吡啶甲酰胺(30g,0.081mol)溶液滴加入溶于二氯甲烷(60mL)的PCl5(95%,26.6g,0.121mol)溶液中。将得到的混合物在5至10℃下搅拌1小时。然后用30分钟将其加热到室温。接着用45分钟将AlCl3(43.1g,0.323mol)分四批加入混合物中,同时保持温度在30℃以下。将混合物搅拌1小时,然后将其倒到冰(300g)上。通过蒸馏除去混合物中的二氯甲烷,随后,将剩下的水溶液加热到80℃保持1小时。将柠檬酸三钠盐二水合物(70g,0.24mol)加入其中,随后用氢氧化钠水溶液(10M,140mL)将其pH值调节至7。加入甲苯(150mL),随后,将溶于甲苯(50mL)的马来酸酐(12.0g,0.122mol)溶液加入其中。将得到的混合物搅拌半小时,用氢氧化钠水溶液(10M,60mL)将混合物的pH值调节至12。将混合物加热至70℃,并进行相分离。用甲苯(2×90mL)进一步萃取水相,用水(90mL)洗涤合并的有机层。HPlC分析表明溶液酮产物量为95%。将产物混合物从甲苯/己烷中重结晶,得到所需的乳白色固体状的三环酮(13.96g,71%)。N-(4-chlorophenyl)-3-[2-(3-chlorophenyl)ethyl]-2-pyridinecarboxamide ( 30 g, 0.081 mol) solution was added dropwise to a solution of PCl 5 (95%, 26.6 g, 0.121 mol) dissolved in dichloromethane (60 mL). The resulting mixture was stirred at 5 to 10°C for 1 hour. It was then allowed to warm to room temperature over 30 minutes. AlCl3 (43.1 g, 0.323 mol) was then added to the mixture in four portions over 45 minutes while keeping the temperature below 30°C. The mixture was stirred for 1 hour, then poured onto ice (300 g). The dichloromethane in the mixture was removed by distillation, and the remaining aqueous solution was heated to 80° C. for 1 hour. Trisodium citrate dihydrate (70 g, 0.24 mol) was added thereto, followed by adjusting its pH to 7 with aqueous sodium hydroxide solution (10 M, 140 mL). Toluene (150 mL) was added, followed by a solution of maleic anhydride (12.0 g, 0.122 mol) dissolved in toluene (50 mL). The resulting mixture was stirred for half an hour, and the pH of the mixture was adjusted to 12 with aqueous sodium hydroxide solution (10 M, 60 mL). The mixture was heated to 70°C and the phases were separated. The aqueous phase was further extracted with toluene (2 x 90 mL), and the combined organic layers were washed with water (90 mL). HPlC analysis indicated 95% ketone product in solution. The product mixture was recrystallized from toluene/hexanes to give the desired tricyclic ketone (13.96 g, 71%) as an off-white solid.
实施例7 Example 7
将5g(85.5mmol)氯化钠、20g(45.7mmol)酰胺 3和100mL氯苯加入装配了磁力搅拌器、温度计和回流冷凝器的250mL三颈烧瓶中。在氮气氛围中,将混合物在室温下搅拌15分钟。将16g(76.8mmol)PCl5加入得到的溶液中,同时保持温度在40℃以下。将反应混合物在30至35℃下搅拌2小时。将15.6g(96.2mmol)FeCl3加入反应混合物,之后,将反应混合物加热至30-35℃保持3小时,接着加热至80-85℃保持约18小时,随后进行HPLC分析。将反应混合物冷却至10-20℃并将50mL丙酮加入其中。将混合物搅拌15分钟,将其慢慢地倒入200mL的30g(224mmol)D,L-苹果酸的水溶液中。在室温下搅拌1小时,随后,用200mL和100mLEtOAc连续地萃取产物。用200mL的20g(149mmol)D,L-苹果酸的水溶液洗涤合并的有机层。将50mL丙酮、20mL甲醇和10mL48%的HBr(88mmol)溶液加入合并的有机层中。将混合物在45℃下搅拌2小时以完全水解,然后用冰浴将其冷却至5-10℃。将沉淀物过滤,用50mL丙酮洗涤,在真空烘箱中于25℃干燥,得到16.1g(82%)的环化产物。5 g (85.5 mmol) of sodium chloride, 20 g (45.7 mmol) of amide 3 and 100 mL of chlorobenzene were added to a 250 mL three-necked flask equipped with a magnetic stirrer, thermometer and reflux condenser. Under nitrogen atmosphere, the mixture was stirred at room temperature for 15 minutes. 16 g (76.8 mmol) of PCl 5 were added to the resulting solution while keeping the temperature below 40 °C. The reaction mixture was stirred at 30 to 35°C for 2 hours. 15.6 g (96.2 mmol) FeCl3 was added to the reaction mixture, after which the reaction mixture was heated to 30-35°C for 3 hours, then to 80-85°C for about 18 hours, followed by HPLC analysis. The reaction mixture was cooled to 10-20°C and 50 mL of acetone was added thereto. The mixture was stirred for 15 minutes and poured slowly into 200 mL of an aqueous solution of 30 g (224 mmol) D,L-malic acid. After stirring at room temperature for 1 h, the product was sequentially extracted with 200 mL and 100 mL of EtOAc. The combined organic layers were washed with 200 mL of an aqueous solution of 20 g (149 mmol) D,L-malic acid. 50 mL of acetone, 20 mL of methanol and 10 mL of 48% HBr (88 mmol) solution were added to the combined organic layers. The mixture was stirred at 45°C for 2 hours to complete the hydrolysis, then it was cooled to 5-10°C with an ice bath. The precipitate was filtered, washed with 50 mL of acetone, and dried in a vacuum oven at 25 °C to yield 16.1 g (82%) of the cyclized product.
尽管结合上述具体的实施方案对本发明进行了描述,但是对于本领域的普通技术人员来说,许多替换、修饰及其变化是显而易见的。所有的这些替换、修饰及其变化都在本发明的精神和范围之内。Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. All such substitutions, modifications and variations are within the spirit and scope of the invention.
Claims (14)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19700398A | 1998-11-20 | 1998-11-20 | |
| US09/197,003 | 1998-11-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1326444A CN1326444A (en) | 2001-12-12 |
| CN1162404C true CN1162404C (en) | 2004-08-18 |
Family
ID=22727622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB998135151A Expired - Lifetime CN1162404C (en) | 1998-11-20 | 1999-11-18 | Process for the synthesis of intermediates useful in the preparation of tricyclic compounds |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1131296A2 (en) |
| JP (2) | JP4663122B2 (en) |
| CN (1) | CN1162404C (en) |
| AR (1) | AR028138A1 (en) |
| AU (1) | AU3790200A (en) |
| CA (1) | CA2351693C (en) |
| CO (1) | CO5150169A1 (en) |
| HK (1) | HK1038698A1 (en) |
| MY (1) | MY121795A (en) |
| PE (1) | PE20001243A1 (en) |
| TW (1) | TW509680B (en) |
| WO (1) | WO2000030589A2 (en) |
| ZA (1) | ZA200103246B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004501081A (en) | 2000-04-18 | 2004-01-15 | シェーリング コーポレイション | Synthesis of intermediates useful in the preparation of tricyclic compounds |
| WO2004058719A1 (en) * | 2002-12-26 | 2004-07-15 | Cadila Healthcare Limited | A process for preparing benzocyclohetapyridin-11-ones |
| CN108218773A (en) * | 2018-02-28 | 2018-06-29 | 朱路英 | A kind of method for preparing resisting allergic rhinitis drug loratadine intermedite |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282233B1 (en) | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
| DE3677842D1 (en) * | 1985-05-13 | 1991-04-11 | Schering Corp | METHOD FOR THE PRODUCTION OF PIPERIDYLIDES-DIHYDRODIBENZO (A, D) CYCLOHEPTENES AND THEIR AZODERIVATES, COMPOUNDS MADE THEREOF AND THEIR USE FOR THE PREPARATION OF MEDICINAL PRODUCTS. |
| US4731447A (en) * | 1985-05-13 | 1988-03-15 | Schering Corporation | Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof |
| US5089496A (en) | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
| CA2245055C (en) * | 1989-02-28 | 2003-03-25 | F. Hoffmann-La Roche Ag | Amidation of pyridines |
| US5672750A (en) * | 1994-12-16 | 1997-09-30 | Eastman Chemical Company | Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride |
| IL117798A (en) * | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases and pharmaceutical compositions comprising them |
| WO1997023478A1 (en) | 1995-12-22 | 1997-07-03 | Schering Corporation | Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases |
| ES2143816T3 (en) * | 1996-05-09 | 2000-05-16 | Lonza Ag | PROCEDURE FOR THE PREPARATION OF ARYLAMIDES FROM HETEROAROMATIC CARBOXYL ACIDS. |
| US5958890A (en) * | 1996-09-13 | 1999-09-28 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| ES2209121T3 (en) * | 1997-03-25 | 2004-06-16 | Schering Corporation | SYNTHESIS OF USEFUL INTERMEDIATES IN THE PREPARATION OF TRICYCLE COMPOUNDS. |
-
1999
- 1999-11-18 JP JP2000583474A patent/JP4663122B2/en not_active Expired - Lifetime
- 1999-11-18 CN CNB998135151A patent/CN1162404C/en not_active Expired - Lifetime
- 1999-11-18 CA CA002351693A patent/CA2351693C/en not_active Expired - Lifetime
- 1999-11-18 TW TW088120161A patent/TW509680B/en not_active IP Right Cessation
- 1999-11-18 AU AU37902/00A patent/AU3790200A/en not_active Abandoned
- 1999-11-18 CO CO99072692A patent/CO5150169A1/en unknown
- 1999-11-18 WO PCT/US1999/026010 patent/WO2000030589A2/en not_active Ceased
- 1999-11-18 AR ARP990105868A patent/AR028138A1/en active IP Right Grant
- 1999-11-18 HK HK02100248.8A patent/HK1038698A1/en unknown
- 1999-11-18 EP EP99972525A patent/EP1131296A2/en not_active Withdrawn
- 1999-11-19 PE PE1999001170A patent/PE20001243A1/en not_active Application Discontinuation
- 1999-11-19 MY MYPI99005048A patent/MY121795A/en unknown
-
2001
- 2001-04-20 ZA ZA200103246A patent/ZA200103246B/en unknown
-
2010
- 2010-03-01 JP JP2010044749A patent/JP2010132701A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN1326444A (en) | 2001-12-12 |
| WO2000030589A2 (en) | 2000-06-02 |
| WO2000030589A3 (en) | 2001-01-04 |
| HK1038698A1 (en) | 2002-03-28 |
| CA2351693C (en) | 2009-01-20 |
| JP4663122B2 (en) | 2011-03-30 |
| EP1131296A2 (en) | 2001-09-12 |
| ZA200103246B (en) | 2002-07-22 |
| TW509680B (en) | 2002-11-11 |
| CO5150169A1 (en) | 2002-04-29 |
| JP2002530307A (en) | 2002-09-17 |
| MY121795A (en) | 2006-02-28 |
| PE20001243A1 (en) | 2000-11-15 |
| AR028138A1 (en) | 2003-04-30 |
| AU3790200A (en) | 2000-06-13 |
| CA2351693A1 (en) | 2000-06-02 |
| JP2010132701A (en) | 2010-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100418950C (en) | Method for preparing quinoline derivatives | |
| WO2007102499A1 (en) | Process for production of 4-oxoquinoline compound | |
| JP4048119B2 (en) | Process for producing 2- (4-chlorobenzoylamino) -3- [2 (1H) -quinollinon-4-yl] propionic acid | |
| TW201806927A (en) | Method for preparing 4-alkoxy-3-(indenyl or alkyl)oxypyridiniumamine | |
| CN1162404C (en) | Process for the synthesis of intermediates useful in the preparation of tricyclic compounds | |
| CN86104611A (en) | The preparation method of therapeutical agent | |
| CN1178918C (en) | Synthesis of Acridine Derivatives of Multiple Disease Resistance Inhibitors | |
| CN1533378A (en) | Process for the preparation of quinazolines | |
| CN105026370B (en) | Asymmetric Synthesis of Substituted Pyrrolidine‑2‑Carboxamides | |
| JP2008533189A (en) | Process for preparing 1-substituted 1H-imidazo [4,5-c] quinolin-4-amine compounds and intermediates therefor | |
| CN1452621A (en) | Process for preparing substd. imidazopyridine compound | |
| CN1147475C (en) | Process for preparation of anti-malarial drugs | |
| CN1105996A (en) | Preparation of imidazopyridine derivative | |
| CN1022920C (en) | Process for preparing aromatic substance of 5-member heterocyclic ring containing nitrogen | |
| US6372909B1 (en) | Synthesis of intermediates useful in preparing tricyclic compounds | |
| CN1244562C (en) | The synthetic method of tricyclic ketone intermediate | |
| KR930010500B1 (en) | Method of preparing cotarin | |
| CN1178919C (en) | Synthetic method of intermediates for the preparation of tricyclic compounds and intermediates therein | |
| CN110526866B (en) | Synthesis method of 2-quinolinone compounds | |
| CN1217937C (en) | Synthesis of intermediates for the preparation of tricyclic compounds | |
| CN116836109B (en) | A cyanoalkyl-substituted quinoline compound and its preparation method | |
| CN115368292B (en) | Benzondoles compound and synthesis method thereof | |
| WO2002070477A1 (en) | 2-methylindole-4-acetic acid, process for producing the same, and process for producing intermediate therefor | |
| CN1505622A (en) | Process for preparing (dioxolenon-4-yl) methyl ester derivatives | |
| JP2015524846A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: MSD CORP. Free format text: FORMER NAME: SCHERING CORP (US) |
|
| CP01 | Change in the name or title of a patent holder |
Address after: new jersey Patentee after: Schering Corporation Address before: new jersey Patentee before: SCHERING CORP (US) |
|
| CX01 | Expiry of patent term |
Granted publication date: 20040818 |
|
| CX01 | Expiry of patent term |